Annals of Military and Health Sciences Research

Published by: Kowsar

The Effect of Systemic Delivery of Bisphosphonates on Trabecular and Cortical Bone Mass of Ovariectomized Rats

Mohammad Hossein Shahrezaee 1 , 2 , Mostafa Shahrezaee 2 , * , Ahmad Oryan 3 , Seyed Akbar Kamali 4 , Saeed Sajadi 2 and Hesam Eskafian 2
Authors Information
1 School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Orthopedic Surgery, School of Medicine, AJA University of Medical Science, Tehran, Iran
3 Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
4 School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Annals of Military and Health Sciences Research: 16 (4); e86830
  • Published Online: December 31, 2018
  • Article Type: Research Article
  • Received: November 27, 2018
  • Revised: December 19, 2018
  • Accepted: December 23, 2018
  • DOI: 10.5812/amh.86830

To Cite: Shahrezaee M H, Shahrezaee M, Oryan A, Kamali S A , Sajadi S , et al. The Effect of Systemic Delivery of Bisphosphonates on Trabecular and Cortical Bone Mass of Ovariectomized Rats, Ann Mil Health Sci Res. Online ahead of Print ; 16(4):e86830. doi: 10.5812/amh.86830.

Copyright © 2019, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006;8(1):28-39. doi: 10.1016/S1098-3597(06)80063-3. [PubMed: 17591574].
  • 2. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep. 2008;10(2):92-6. doi: 10.1007/s11926-008-0017-6. [PubMed: 18460262].
  • 3. Riek AE, Towler DA. The pharmacological management of osteoporosis. Mo Med. 2011;108(2):118-23. [PubMed: 21568234]. [PubMed Central: PMC3597219].
  • 4. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability. Bone. 2011;49(1):50-5. doi: 10.1016/j.bone.2010.08.008. [PubMed: 20727997]. [PubMed Central: PMC2994972].
  • 5. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150-62. doi: 10.1542/peds.2006-2023H. [PubMed: 17332236].
  • 6. Mardas N, Busetti J, de Figueiredo JA, Mezzomo LA, Scarparo RK, Donos N. Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid. Clin Oral Implants Res. 2017;28(3):362-71. doi: 10.1111/clr.12810. [PubMed: 26920844].
  • 7. Gunes N, Dundar S, Saybak A, Artas G, Acikan I, Ozercan IH, et al. Systemic and local zoledronic acid treatment with hydroxyapatite bone graft: A histological and histomorphometric experimental study. Exp Ther Med. 2016;12(4):2417-22. doi: 10.3892/etm.2016.3685. [PubMed: 27698743]. [PubMed Central: PMC5038845].
  • 8. Cardemil C, Omar OM, Norlindh B, Wexell CL, Thomsen P. The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomised rat model. Biomaterials. 2013;34(5):1546-61. doi: 10.1016/j.biomaterials.2012.11.003. [PubMed: 23182921].
  • 9. Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab. 2003;21(6):421-7. doi: 10.1007/s00774-003-0438-2. [PubMed: 14586800].
  • 10. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [PubMed: 18214569].
  • 11. Crandall C. Risedronate: A clinical review. Arch Intern Med. 2001;161(3):353-60. doi: 10.1001/archinte.161.3.353. [PubMed: 11176760].
  • 12. Khajuria DK, Razdan R, Mahapatra DR. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats. J Orthop Sci. 2014;19(4):646-56. doi: 10.1007/s00776-014-0557-8. [PubMed: 24668309].
  • 13. Shahrezaee M, Oryan A, Bastami F, Hosseinpour S, Shahrezaee MH, Kamali A. Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats. Endocrine. 2018;60(1):138-50. doi: 10.1007/s12020-018-1531-6. [PubMed: 29372484].
  • 14. Oryan A, Bigham-Sadegh A, Abbasi-Teshnizi F. Effects of osteogenic medium on healing of the experimental critical bone defect in a rabbit model. Bone. 2014;63:53-60. doi: 10.1016/j.bone.2014.02.010. [PubMed: 24582803].
  • 15. Auerkari E, Suhartono A, Djamal N, Verisqa F, Suryandari D, Kusdhany L, et al. CRP and IL-1B gene polymorphisms and CRP in blood in periodontal disease. Open Dent J. 2013;7:88-93. doi: 10.2174/1874210601307010088. [PubMed: 24009648]. [PubMed Central: PMC3758952].
  • 16. Kharode YP, Sharp MC, Bodine PV. Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol. 2008;455:111-24. doi: 10.1007/978-1-59745-104-8_8. [PubMed: 18463814].
  • 17. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008;58(5):424-30. [PubMed: 19004367]. [PubMed Central: PMC2707131].
  • 18. Ayan M, Dolanmaz D, Mihmanli A, Ayan A, Kurkcu M. The effect of systemically administrated zoledronic acid on the osseointegration of dental implants. Oral Dis. 2012;18(8):802-8. doi: 10.1111/j.1601-0825.2012.01948.x. [PubMed: 22712806].
  • 19. Yano T, Yamada M, Inoue D. Effect of sequential treatment with bisphosphonates after teriparatide in ovariectomized rats: A direct comparison between risedronate and alendronate. Calcif Tissue Int. 2017;101(1):102-10. doi: 10.1007/s00223-017-0263-6. [PubMed: 28337514]. [PubMed Central: PMC5486924].
  • 20. Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503-11. doi: 10.1002/jbmr.238. [PubMed: 20814967].
  • 21. Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: The TRIO study. Osteoporos Int. 2014;25(12):2729-41. doi: 10.1007/s00198-014-2817-z. [PubMed: 25074351].
  • 22. Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, et al. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012;97(12):4481-90. doi: 10.1210/jc.2012-2804. [PubMed: 23024190]. [PubMed Central: PMC3591679].
  • 23. Li GW, Xu Z, Chang SX, Zhou L, Wang XY, Nian H, et al. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats. Endocrinology. 2014;155(12):4731-8. doi: 10.1210/en.2014-1359. [PubMed: 25243855].
  • 24. Abdel-Sater KA, Mansour H. Bone biomarkers of ovariectomised rats after leptin therapy. Bratisl Lek Listy. 2013;114(6):303-7. [PubMed: 23731039].
  • 25. Casado-Diaz A, Santiago-Mora R, Dorado G, Quesada-Gomez JM. Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells. Arch Med Res. 2013;44(5):325-34. doi: 10.1016/j.arcmed.2013.05.002. [PubMed: 23867791].
  • 26. Myoung H, Park JY, Choung PH. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. J Periodontal Res. 2001;36(4):244-51. doi: 10.1034/j.1600-0765.2001.036004244.x. [PubMed: 11519698].
  • 27. Toker H, Ozdemir H, Ozer H, Eren K. A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: A histologic and histomorphometric study in a rat calvarial defect model. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(5 Suppl):S146-52. doi: 10.1016/j.oooo.2011.09.027. [PubMed: 23063391].
  • 28. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development. J Oral Maxillofac Surg. 2009;67(5 Suppl):13-8. doi: 10.1016/j.joms.2008.10.005. [PubMed: 19371810].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments